Is an ideal nasal drop able to reduce all symptoms of allergic rhinitis?
No Thumbnail Available
Date
2020
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
In the majority of cases, allergic rhinitis (AR) has its onset in children or adolescents, with the cardinal symptomatology of repeated sneezing, nasal pruritus, discharge, and a blocked nose. The customary way to classify AR is into seasonal and perennial variants, reflecting the allergenic underpinning of the disorder, but the World Health Organisation (WHO), in its Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, employs a classification scheme dividing AR into intermittent or persistent types, based on the symptomatic duration. The current treatment modalities for AR are nasal steroids, nasal decongestants, anticholinergics, antihistamines, and panthenol. A novel pharmaceutical formulation that provides all the effects of the abovementioned drugs may be unique and has significant benefits such as single drug usage, cost-effectiveness, lesser side effects, etc. The proposed formulation enables to combine the anti-inflammatory, antihistaminic, decongestant, anticholinergic, and hydrating effects of these drugs into a single medicine. © Springer Nature Switzerland AG 2021.